Question Bank › Ground-level proof points accumulating

Ground-level proof points accumulating

Ground-level proof points accumulating: management narrates several small, named, recent wins and treats them as the lea

Calls Tested
322
Answered YES
8
Hit Rate
2.5%
rare by design

ANI Pharmaceuticals, Inc. (ANIP) — this company's answers

NO on the Q4 2016 call 2017-03-02 B+
The model's full reasoning — Q4 2016 call → NOWe need answer YES/NO based on transcript. Need analyze. Question asks: On this call, does management's account of just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from inside business, each identifiable on its own — AND does management explicitly treat these accumulating episodes as LEADING EDGE of broader improvement still early? Need use only transcript. Need decide. Let's parse transcript. Management (Art, Steve) discusses results. They mention product launches: "These launches, annualized for 2017, will help to contribute to continued generic revenue growth." They mention "we terminated our distribution agreement for Hydroxyprogesterone Caproate or HPC... received cash and an undisclosed NDA. We hope to launch the NDA as an authorized generic in near future." They mention Corticotropin project advances: "begun work on manufacturing raw material batches, analytical method development and have recently hired Karen Quinn to lead regulatory filing strategy." They mention "we acquired and launched Inderal XL and InnoPran XL" (recently). They mention "we just launched the two products that we acquired on the next day after we acquired the products." They mention "we have a robust pipeline of product opportunities and anticipate launching several new products in 2017." They mention "10 product introductions during the year" in Q4 generic revenue. Key contributors: Fenofibrate, Propranolol ER, EES, Mesalamine, Nilutamide. They mention "we hired 45 full time employees in 2016, increasing headcount by 32% primarily to support manufacturing facilities in Minnesota." They mention "we have begun work on manufacturing raw material batches, analytical method development and have recently hired Karen Quinn." They mention "we terminated distribution agreement for HPC" as event. But are these "several small, concrete, ground-level wins" individually described? The call is mostly financial results, guidance. They mention product launches as contributors. But do they describe specific episodes? They name products launched: Fenofibrate, Propranolol ER, EES, Mesalamine, Nilutamide. But no detail about each launch, no specific customer, no specific milestone. They are just product names in a list.

← Back to the full ANIP analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from inside the business, each one identifiable on its own — AND does management explicitly treat these accumulating episodes as the LEADING EDGE of a broader improvement that is still early? Answer YES when BOTH halves come through in management's own words, in whatever form fits the business: (1) AT LEAST THREE DISTINCT, NAMED OR INDIVIDUALLY IDENTIFIABLE EPISODES FROM THE RECENT PERIOD. Management recounts multiple separate ground-level events that actually happened recently — each described specifically enough that a listener could tell the episodes apart and could later check them. The episodes may take whatever form fits the industry: a particular customer, account, or partner that signed, reordered, expanded, or went live; a particular site, store, plant, line, rig, clinic, or facility that opened, hit a milestone, or reached a new performance level; a particular product, program, or offering that shipped its first units, won its first placements, or crossed a threshold; a particular region, channel, or contract that turned on or stepped up. What matters is the GRANULARITY and RECENCY: these are individually small, freshly occurred, operator-level facts — the kind of detail only people close to the business would narrate — not aggregate results, percentages, themes, or claims like "demand was strong across the board." (2) MANAGEMENT ITSELF CONNECTS THE EPISODES INTO A BUILDING PATTERN THAT IS STILL EARLY. Management explicitly draws the line from these individual episodes to a larger developing trajectory — conveying, in its own voice, that these wins are instances of the same underlying thing, that more of the same kind are already forming or arriving, and that the pattern's contribution to reported results is only beginning, so most of it lies ahead. The generalization must be management's own act, grounded in the recounted episodes — not a hope, a market-size claim, or an analyst's summary. Answer NO if the call's positive story is carried mainly by aggregates — overall growth rates, segment percentages, or general demand commentary — without several individually identifiable recent episodes. NO if fewer than three distinct episodes are described, or the episodes are really one event told from different angles. NO if the episodes are plans, pipeline items, letters of intent, or hoped-for events rather than things that already happened. NO if the episodes are the routine cadence this company always reports (its usual pace of customer additions, standard seasonal openings) and management does not present their accumulation as new or building. NO if management recounts the episodes but never itself connects them into a broader, still-early pattern with more arriving. NO if the episodes chiefly explain problems, or the call is mainly defense of weak results. NO if the pattern-framing appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
TOST Toast, Inc. Q4 2022 2023-02-16 C+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

AU · Q2 2018 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple specific, recent operational episodes: Kibali’s underground ramp-up with automated ore handling system and vertical shaft integration; Iduapriem’s CIL tank conversion and grade/tonnage gains; Sunrise Dam’s Recovery Enhancement Project plus new mining strategies; Tropicana’s second 6-MW ball mill installation; Siguiri’s CIL circuit milestone; and 338 tracked Operational Excellence projects.
BXP · Q1 2022 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple distinct, named episodes from the recent period: the 73,000 sq ft recapture/release at 77 CityPoint with a 15% rent increase and 7.
CRGO · Q1 2024 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...

More from the question bank

Conversion calendar in handFresh order-of-magnitude reference changeBetting on a customer they cannot yet nameOutside actors already movingWinning more per swing than they used to — aPriced for a smaller companyAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.